337 related articles for article (PubMed ID: 11801545)
1. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of two fluorouracil administration regimens for colorectal cancer.
Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
4. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.
Rafi I; Taylor GA; Calvete JA; Boddy AV; Balmanno K; Bailey N; Lind M; Calvert AH; Webber S; Jackson RC
Clin Cancer Res; 1995 Nov; 1(11):1275-84. PubMed ID: 9815922
[TBL] [Abstract][Full Text] [Related]
6. Mature results from three large controlled studies with raltitrexed ('Tomudex').
Cunningham D
Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851
[TBL] [Abstract][Full Text] [Related]
7. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
Yeh KH; Yeh SH; Hsu CH; Wang TM; Ma IF; Cheng AL
Br J Cancer; 2000 Dec; 83(11):1510-5. PubMed ID: 11076661
[TBL] [Abstract][Full Text] [Related]
8. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Nutting C; Folkes A
Clin Oncol (R Coll Radiol); 1999; 11(1):66. PubMed ID: 10194593
[No Abstract] [Full Text] [Related]
9. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
10. New drugs in therapy of colorectal cancer: preclinical studies.
Rustum YM; Cao S
Semin Oncol; 1999 Dec; 26(6):612-20. PubMed ID: 10606254
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
13. Raltitrexed: optimism and reality.
Wilson KS; Malfair Taylor SC
Expert Opin Drug Metab Toxicol; 2009 Nov; 5(11):1447-54. PubMed ID: 19863453
[TBL] [Abstract][Full Text] [Related]
14. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
16. [Recent advance in chemotherapy for advanced colorectal cancer].
Aiba K
Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
18. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM
J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
[TBL] [Abstract][Full Text] [Related]
19. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
Avallone A; Di Gennaro E; Silvestro L; Iaffaioli VR; Budillon A
Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
[TBL] [Abstract][Full Text] [Related]
20. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
Papamichael D
Oncologist; 1999; 4(6):478-87. PubMed ID: 10631692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
